FR3115680B1 - Compositions for the treatment of psoriasis. - Google Patents

Compositions for the treatment of psoriasis. Download PDF

Info

Publication number
FR3115680B1
FR3115680B1 FR2011260A FR2011260A FR3115680B1 FR 3115680 B1 FR3115680 B1 FR 3115680B1 FR 2011260 A FR2011260 A FR 2011260A FR 2011260 A FR2011260 A FR 2011260A FR 3115680 B1 FR3115680 B1 FR 3115680B1
Authority
FR
France
Prior art keywords
compositions
psoriasis
treatment
psoriatic
hesperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2011260A
Other languages
French (fr)
Other versions
FR3115680A1 (en
Inventor
Luc Lefeuvre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Dermatologiques dUriage SAS
Original Assignee
Laboratoires Dermatologiques dUriage SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Dermatologiques dUriage SAS filed Critical Laboratoires Dermatologiques dUriage SAS
Priority to FR2011260A priority Critical patent/FR3115680B1/en
Publication of FR3115680A1 publication Critical patent/FR3115680A1/en
Application granted granted Critical
Publication of FR3115680B1 publication Critical patent/FR3115680B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composition comprenant à titre de principe actif de l’alpha-glucosyl-hespéridine pour lutter contre la réaction inflammatoire induite par le peptide antibactérien LL-37 dans les peaux humaines psoriasiques. Les compositions sont destinées à être appliquées sur les lésions de peaux psoriasiques.Composition comprising as active ingredient alpha-glucosyl-hesperidin to fight against the inflammatory reaction induced by the antibacterial peptide LL-37 in psoriatic human skin. The compositions are intended to be applied to psoriatic skin lesions.

FR2011260A 2020-11-03 2020-11-03 Compositions for the treatment of psoriasis. Active FR3115680B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR2011260A FR3115680B1 (en) 2020-11-03 2020-11-03 Compositions for the treatment of psoriasis.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2011260A FR3115680B1 (en) 2020-11-03 2020-11-03 Compositions for the treatment of psoriasis.
FR2011260 2020-11-03

Publications (2)

Publication Number Publication Date
FR3115680A1 FR3115680A1 (en) 2022-05-06
FR3115680B1 true FR3115680B1 (en) 2023-04-21

Family

ID=74125459

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2011260A Active FR3115680B1 (en) 2020-11-03 2020-11-03 Compositions for the treatment of psoriasis.

Country Status (1)

Country Link
FR (1) FR3115680B1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105031A1 (en) * 2001-11-06 2003-06-05 Rosenbloom Richard A. Methods for the treatment of skin disorders
FR2932986B1 (en) * 2008-06-26 2010-12-10 Michele Evrard REGENERATING COMPOSITION OF THE SKIN
US10111821B2 (en) * 2011-11-03 2018-10-30 Applied Biology, Inc. Methods and compositions for administering a specific wavelength phototherapy
FR3022139B1 (en) * 2014-06-12 2016-07-22 Laboratoires Dermatologiques D'uriage NEW COMPOSITIONS FOR THE TREATMENT OF SKIN FLAVORS AND ROSACEA
CN106943594A (en) 2017-03-29 2017-07-14 西安交通大学 Psoriasin antibody and the antibody of LL 37 are preparing the application in preventing and treating the medicine of psoriasis

Also Published As

Publication number Publication date
FR3115680A1 (en) 2022-05-06

Similar Documents

Publication Publication Date Title
EP4331668A3 (en) Compounds for inhibiting nlrp3 and uses thereof
AR105808A1 (en) AMIDA COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
DE60325379D1 (en) Composition containing 6-Ä3- (1-adamantyl) -4-methoxyphenyl-2-naphthanoic acid for the treatment of dermatological diseases
RU2013141845A (en) PHARMACEUTICAL COMPOSITION IN THE FORM OF A CREAM CONTAINING OXYMETAZOLINE FOR THE TREATMENT OF ROSATSEA SYMPTOMS
ATE396973T1 (en) BENZYL ETHER AND BENZYLAMINO BETA SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
JP2012531448A5 (en)
WO2020212760A3 (en) Compounds and methods for the treatment of ocular disorders
EA200700044A1 (en) COMPOSITION FOR LOCAL APPLICATION
JP2007522256A5 (en)
ECSP22040362A (en) 1,2,4OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS
FR3130555B3 (en) Composition comprising at least one boswellic acid and/or at least one plant extract comprising at least one boswellic acid for topical use in the treatment of inflammatory skin diseases
MX2012013642A (en) Topical pharmaceutical compositions comprising mometasone furoate.
JP6815006B2 (en) Acne strain selective antibacterial agent
CN116322624A (en) Composition for promoting skin microbiota
FR3115680B1 (en) Compositions for the treatment of psoriasis.
ES2880437T3 (en) New topical compositions comprising usnic acid and its therapeutic use
HUE028120T2 (en) Compositions for the treatment of peripheral ulcers of various origins
FR3094229B1 (en) Topical composition for the treatment of bad body odor, in particular halitosis
BR112022010498A2 (en) KETOPROFEN COCRYSTAL AND ITS PREPARATION, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME AND THEIR USE
RU2014101705A (en) FILM FORMING COMPOSITION AND ITS APPLICATION FOR TREATING HERPES
RU2007132165A (en) ADAPALEN FOR LONG TREATMENT OF ORDINARY ACNS
PA8579701A1 (en) BETA-LACTAMASA INHIBITOR PROFARMACO
EP3164110B1 (en) Pharmaceutical compositions for the treatment of psoriasis
BR112021011368A2 (en) Ketoprofen cocrystal, compositions comprising the same, process for their production and uses thereof
US20190060260A1 (en) N-bromotaurine solutions and emulsions against abnormal cells

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20220506

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4